Enhanced Immunotherapy Based on Photodynamic Therapy for Both Primary and Lung Metastasis Tumor Eradication
Source abstract
Abstract
Metastasis and recurrence are two unavoidable and intractable problems in cancer therapy, despite various robust therapeutic approaches. Currently, it seems that immunotherapy is an effective approach to solve these problems, but the high heterogeneity of tumor tissue, inefficient presentation of tumor antigen, and deficient targeting ability of therapy usually blunt the efficacy of immunotherapy and hinder its clinical application. Herein, an approach based on combining photodynamic and immunological therapy was designed and developed. We synthesized a chimeric peptide, PpIX-1MT, which integrates photosensitizer PpIX with immune checkpoint inhibitor 1MT via a caspase-responsive peptide sequence, Asp-Glu-Val-Asp (DEVD), to realize a cascaded synergistic effect. The PpIX-1MT peptide could form nanoparticles in PBS and accumulate in tumor areas via the enhanced penetration retention effect. Upon 630 nm light irradiation, the PpIX-1MT nanoparticles produced reactive oxygen species, induced apoptosis of cancer cells, and thus facilitated the expression of caspase-3 and the production of tumor antigens, which could trigger an intense immune response. The subsequently released 1MT upon caspase-3 cleavage could further strengthen the immune system and help to activate CD8 + T cells effectively. This cascaded synergistic effect could inhibit both primary and lung metastasis tumor effectively, which may provide the solution for solving tumor recurrence and metastasis clinically.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Photodynamic Therapy Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry, Wuhan University, Wuhan 430072, People’s Republic of China
Department of Pathophysiology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei 430072, People’s Republic of China
Department of Pathology, Hubei Cancer Hospital, Wuhan, Hubei 430079, People’s Republic of China
The Institute for Advanced Studies (IAS), Wuhan University, Wuhan 430072, People’s Republic of China
Funding
National Natural Science Foundation of China
References (47)
Show source-provided references
1. 10.3322/caac.2133210.3322/caac.21332 ↗
2. 10.3322/caac.2139710.3322/caac.21397 ↗
3. 10.3322/caac.2131910.3322/caac.21319 ↗
4. 10.1038/nrclinonc.2016.6610.1038/nrclinonc.2016.66 ↗
5. 10.1002/adfm.20170212210.1002/adfm.201702122 ↗
6. 10.1002/adfm.20160321210.1002/adfm.201603212 ↗
7. 10.1021/acs.nanolett.6b0143210.1021/acs.nanolett.6b01432 ↗
8. 10.3322/caac.2120810.3322/caac.21208 ↗
9. 10.1021/acsnano.5b0666310.1021/acsnano.5b06663 ↗
10. 10.1126/scitranslmed.aae010510.1126/scitranslmed.aae0105 ↗
11. 10.1038/nrc.2016.9710.1038/nrc.2016.97 ↗
12. 10.1126/science.aac790210.1126/science.aac7902 ↗
13. 10.1126/science.aaa817210.1126/science.aaa8172 ↗
14. 10.1038/nrc323910.1038/nrc3239 ↗
15. 10.1038/nrc263910.1038/nrc2639 ↗
16. 10.1038/nrc158610.1038/nrc1586 ↗
17. 10.1084/jem.189.9.136310.1084/jem.189.9.1363 ↗
18. 10.1126/science.281.5380.119110.1126/science.281.5380.1191 ↗
19. 10.1172/JCI3117810.1172/JCI31178 ↗
20. 10.1021/jacs.6b0666310.1021/jacs.6b06663 ↗
21. 10.1002/adfm.20170022010.1002/adfm.201700220 ↗
22. 10.1021/acsnano.7b0253310.1021/acsnano.7b02533 ↗
23. 10.1021/acsnano.6b0415610.1021/acsnano.6b04156 ↗
24. 10.1021/acsnano.5b0424310.1021/acsnano.5b04243 ↗
25. 10.1038/s41467-017-01050-010.1038/s41467-017-01050-0 ↗
26. 10.1021/acsnano.7b0071510.1021/acsnano.7b00715 ↗
27. 10.1038/ncomms1249910.1038/ncomms12499 ↗
28. 10.1021/jacs.6b0953810.1021/jacs.6b09538 ↗
29. 10.1038/ncomms1319310.1038/ncomms13193 ↗
30. 10.1016/j.biomaterials.2017.06.03110.1016/j.biomaterials.2017.06.031 ↗
31. 10.1021/ja411811w10.1021/ja411811w ↗
32. 10.1021/ja306458810.1021/ja3064588 ↗
33. 10.1021/ja992881j10.1021/ja992881j ↗
34. 10.1111/j.1399-3011.1992.tb00291.x10.1111/j.1399-3011.1992.tb00291.x ↗
35. 10.1073/pnas.85.15.540910.1073/pnas.85.15.5409 ↗
36. 10.1002/adfm.20140319010.1002/adfm.201403190 ↗
37. 10.1002/adfm.20150059010.1002/adfm.201500590 ↗
38. 10.1016/j.biomaterials.2011.02.00910.1016/j.biomaterials.2011.02.009 ↗
39. 10.1038/nri.2016.10710.1038/nri.2016.107 ↗
40. 10.1146/annurev-immunol-032712-10000810.1146/annurev-immunol-032712-100008 ↗
41. 10.1016/j.biomaterials.2016.06.03210.1016/j.biomaterials.2016.06.032 ↗
42. 10.1158/0008-5472.CAN-07-162210.1158/0008-5472.CAN-07-1622 ↗
43. 10.1038/gt.2013.8610.1038/gt.2013.86 ↗
44. 10.1158/0008-5472.CAN-05-441210.1158/0008-5472.CAN-05-4412 ↗
45. 10.1126/science.290.5497.171710.1126/science.290.5497.1717 ↗
46. 10.1016/j.immuni.2013.07.01210.1016/j.immuni.2013.07.012 ↗
47. 10.1016/j.immuni.2013.07.00510.1016/j.immuni.2013.07.005 ↗